Evidence map›Paper›PMID 40510348›Full record

ArticleFrontiers in immunology2025

A nomogram for predicting unfavorable outcomes of antituberculosis treatment among individuals with AIDS combined with pulmonary tuberculosis in China.

Xiaoxu Han, Jin Sun, Yuan Gao, Hongxia Yan, Xiangchuan He, Yuanyuan Ma, Peng Xu, Ning Ding, Xin Zhang, Meixin Ren and 3 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Xiaoxu Han *Beijing Key Laboratory for HIV/AIDS Research, Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Jin Sun *Beijing Key Laboratory for HIV/AIDS Research, Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Yuan Gao *Beijing Key Laboratory for HIV/AIDS Research, Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Hongxia YanBeijing Key Laboratory for HIV/AIDS Research, Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Xiangchuan HeScientific and Technological Achievement Transformation Center, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Yuanyuan MaScientific and Technological Achievement Transformation Center, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Peng XuBeijing Key Laboratory for HIV/AIDS Research, Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Ning DingBeijing Key Laboratory for HIV/AIDS Research, Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Xin ZhangBeijing Key Laboratory for HIV/AIDS Research, Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Meixin RenBeijing Key Laboratory for HIV/AIDS Research, Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Taiyi JiangBeijing Key Laboratory for HIV/AIDS Research, Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Tong ZhangBeijing Key Laboratory for HIV/AIDS Research, Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Bin SuBeijing Key Laboratory for HIV/AIDS Research, Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Acquired Immune Deficiency Syndrome (AIDS) combined with tuberculosis (TB) is one of the key factors affecting global TB control, and timely and effective treatment is essential to improve the prognosis in this population. However, data from the WHO have shown that patients with AIDS combined with TB have a lower anti-TB treatment success rate than HIV-negative individuals do, which may lead to an increased incidence of treatment relapse and drug resistance. Therefore, exploring the risk factors affecting the outcome of anti-TB treatment in patients with AIDS combined with TB and developing relevant predictive models will help clinicians rapidly identify patients at greater risk of treatment failure, which is highly valuable for clinical management. Methods: We conducted a retrospective cohort study including inpatients with AIDS combined with pulmonary tuberculosis (PTB) who were treated at Beijing Youan Hospital between January 2020 and January 2024. The baseline data and laboratory test data of all enrolled patients were collected from the electronic medical records system. We randomly divided the participants into a training set and a validation set at a ratio of 2:1 and established a LASSO Cox model on the basis of the training set to identify risk factors affecting the outcome of anti-TB treatment. The selected prognostic factors were then used to construct the final Cox model, which was visualized using a nomogram. The receiver operating characteristic (ROC) curves, concordance index (C-index), and calibration curves of the training set and validation set were used to evaluate the discrimination ability and consistency of the model, respectively. Decision curve analysis (DCA) was used to assess the clinical applicability of the prognostic models. Patients were subsequently risk stratified according to the optimal cutoff value selected by X-tile software for better clinical decision-making by clinicians. Results: A total of 203 inpatients with AIDS combined with PTB were enrolled in this study, including 141 (69.5%) with treatment success and 62 (30.5%) with unfavorable outcome. The results of the LASSO Cox regression model revealed that the CRP/albumin ratio (CAR), extrapulmonary disseminated tuberculosis, other pulmonary infectious diseases, and pulmonary cavitation were independent risk factors for unfavorable outcomes in patients with AIDS combined with PTB, whereas the CD4 Conclusion: We identified prognostic factors for unfavorable anti-TB treatment outcomes and constructed a predictive nomogram to assess the risk of treatment failure in patients with AIDS combined with PTB. Our model performed satisfactorily and can be used for the clinical screening and management of high-risk patients.

Indexed as

Acquired Immunodeficiency SyndromeAntitubercular AgentsNomogramsTuberculosis, PulmonaryAdultChinaFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesRisk FactorsTreatment OutcomeAntitubercular AgentsAIDSantituberculosis treatmentLASSO Cox modelnomogrampulmonary tuberculosisrisk stratificationtreatment outcome

Identifiers

PMID40510348
PMCPMC12158956

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.